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OBJECTIVES: Sinus Node Disease (SND) is a very common
indication for cardiac pacemakers. In most cases patients have
dual-chamber (DDD) pacing systems implanted. Recent studies
showed beneﬁts of atrial pacing (AAI) rather than DDD. Not
infrequently subsequent atrioventricular block develops and
upgrade of AAI to DDD is necessary, what creates additional
costs. The aim: to compare costs of primary DDD pacemaker
implantation to primary AAI implantation, in patients without
initial DDD indications. METHODS: The cost comparison
analysis was based on deterministic model in the time window
of 10 years. Model assumptions: pacemaker battery longevity:
AAI—8y.; DDD—6y. The rate of upgrade necessity was taken
from the observation of 752 SND patients who had AAI
implanted between 1993 and 1997. Records of patients were
examined to ﬁnd cases requiring further upgrade procedure. The
rate of upgrade to DDD was 19.1% within a mean observational
period 7.4 years. Perspective: public health care payer. Linear
costs depreciation; 5% discount rate. Sensitivity analysis: for
upgrade to DDD rate and procedure costs. RESULTS: Projected
to 10 years rate of upgrade was 25.8%. Cost of primary 
DDD approach was $4719 PPP; primary AAI approach—$3804
PPP; cost of hypothetical (ideal) approach in which all patients
that would need upgrade in the future were identiﬁed 
before implantation was $3505 PPP. Primary DDD would
become equal to primary AAI strategy if upgrade rate was 56%
or more. The lower relative DDD costs the lower was the equal-
ity upgrade rate, and the higher absolute differences the more
beneﬁcial was AAI strategy. CONCLUSIONS: Implantation of
AAI PM in SND patients without DDD indications is cost saving
comparing to DDD in every patient. Better identiﬁcation of
patients who will need upgrade to DDD may bring additional
savings.
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OBJECTIVE: To assess the cost-effectiveness (CE) of rosuvas-
tatin compared to atorvastatin and simvastatin in high-risk
patients in routine clinical practice. METHODS: Medical charts
of 24,225 patients with Coronary Heart Disease (or its equiva-
lent) were reviewed at 500 physician ofﬁces in the Midwest.
Patients between the ages of 18 and 79 years who initiated either
atorvastatin, rosuvastatin or simvastatin treatment; and had a
lipid panel within 90 days before and 4 weeks after initiating
statin therapy were included in the study. Effectiveness [reduc-
tion in low density lipoprotein cholesterol (LDL-C) and achieve-
ment of National Cholesterol Educational Program Adult
Treatment Panel III LDL-C goal] estimates were derived using
multivariate approach. Annual direct medical costs [wholesale
acquisition cost of statins and titration] were included. A deci-
sion analytic CE model, from payer perspective, was constructed
to compute incremental cost effectiveness ratios (ICERs) in terms
of incremental cost/incremental percent change in LDL-C and
incremental cost/incremental percent of patients reaching goal
for rosuvastatin compared to atorvastatin and simvastatin.
RESULTS: Rosuvastatin patients (n = 63) were slightly younger
and had higher baseline LDL-C, than either atorvastatin (n =
480) or simvastatin (n = 232) patients. In the base case analysis,
rosuvastatin had lowest overall annualized cost followed by ator-
vastatin and simvastatin. Using adjusted effectiveness estimates,
as compared to atorvastatin and simvastatin, rosuvastatin had
the lowest cost/LDL-C reduction ($33.27 and $55.43 vs. $23.9,
respectively), and cost/LDL-C goal attainment ($1708 and
$2893 vs. $1260, respectively). Incremental CE analysis indi-
cated that rosuvastatin dominated both atorvastatin and sim-
vastatin. A signiﬁcant reduction in price of simvastatin was
required to attain the same level of CE as rosuvastatin. Results
were most sensitive to acquisition costs of statins. CONCLU-
SION: Rosuvastatin is cost-effective as compared to atorvastatin
and simvastatin in terms of cost per LDL-C reduction, and cost
per patient reaching goal in managing hyperlipidemia among
high-risk patients in routine clinical practice.
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OBJECTIVES: A decision analysis model was developed to eval-
uate the cost-effectiveness of statins available by prescription
(Rx) versus over-the-counter (OTC) from a societal perspective.
METHODS: Beginning with a deterministic baseline of average
costs and effectiveness of statin drugs available in the U.S., a
decision tree model was constructed to estimate the cost-
effectiveness comparing the statins available by Rx and OTC.
We used decision analysis methods to determine the cost-
effectiveness ratios (CERs) of Rx versus OTC strategies for the
cholesterol lowering statins from a US societal perspective. Sen-
sitivity analysis was performed on the CERs to examine the
various assumptions pertaining to the potential variability of key
variables. RESULTS: Given the baseline assumptions in the
model, it was found that OTC statins were more cost-effective
as compared to the prescription statins. Comparing different
statin agents, it was observed that OTC rosuvastatin was the
most cost-effective cholesterol lowering drug among the avail-
able statins in the US market. The projections estimated that all
the available statin agents were dominated by rosuvastatin.
Rosuvastatin had a baseline total annual average health care cost
of $1292 (Rx) and $1242 (OTC) and an average LDL reduction
of 54%. The average costs for all lipid lowering statin therapies
were $1356 (Rx) and $1306 (OTC) and CERs were observed as
$3277 (OTC) versus $3405 (Rx). CONCLUSIONS: The better
CERs of OTC statin therapy were found to be stable over a wide
variety of assumptions about drug efﬁcacy and costs. To attain
the potential beneﬁts and improve clinical outcomes suggested
in this economic decision model, it would be necessary to provide
adequate knowledge to the patients regarding cholesterol level
testing and monitor potential increases in adverse drug events.
OTC statins would potentially increase therapy access to a larger
population, necessitating the need for appropriate self-monitor-
ing and therapy management.
